Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.52 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CA4 | P22748 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5933377 | 0.91 | TDP1 (0.66) | MEN1KMT2ANPC1RAB9ATDP1 | |
| SCHEMBL2310278 | 0.91 | RCE1 (0.54) | MEN1KMT2ANPC1RAB9ATDP1 | |
| SCHEMBL4467147 | 0.89 | RCE1 (0.52) | MEN1KMT2ANPC1RAB9ATDP1 | |
| SCHEMBL2315734 | 0.89 | RCE1 (0.52) | MEN1KMT2ANPC1RAB9ATDP1 | |
| SCHEMBL1901574 | 0.89 | RCE1 (0.52) | MEN1KMT2ANPC1RAB9ATDP1 | |
| SCHEMBL26665230 | 0.87 | RCE1 (0.50) | MEN1KMT2ANPC1RAB9ATDP1 | |
| SCHEMBL2186353 | 0.86 | RCE1 (0.56) | MEN1KMT2ANPC1RAB9ATDP1 | |
| SCHEMBL15111089 | 0.86 | RCE1 (0.68) | MEN1KMT2ANPC1RAB9ATDP1 | |
| SCHEMBL3422890 | 0.86 | MEN1 (0.56) | MEN1KMT2ANPC1RAB9ATDP1 | |
| SCHEMBL15265794 | 0.85 | MAOA (0.54) | MEN1KMT2ANPC1RAB9ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6544987-B2 | Pyrrolidine or piperidine sulfonyl compounds; stimulate neurite outgrowth in nerve cells leading to nerve regeneration for treatment of hair loss, memory loss or vision disorders | PFIZER INC. | 2003-04-08 | — | — | US | disclosed |
| EP-1237869-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR STIMULATING NEURONAL GROWTH AND ELONGATION | AGOURON PHARMACEUTICALS, INC. (US) | 2002-09-11 | — | — | EP | disclosed |
| US-20020061881-A1 | Compounds, compositions, and methods for stimulating neuronal growth and elongation | AGOURON PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | disclosed |
| WO-2001040185-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR STIMULATING NEURONAL GROWTH AND ELONGATION | AGOURON PHARMACEUTICALS, INC. (US) | 2001-06-07 | — | — | WO | disclosed |
| US-5011938-A | Antimicrobials | ELI LILLY AND COMPANY (US) | 1991-04-30 | — | — | US | disclosed |
| US-4940718-A | BACTERICIDES | ELI LILLY AND COMPANY (US) | 1990-07-10 | — | — | US | disclosed |
| US-4902707-A | Bicyclic pyrazolidinones, compositions and use | ELI LILLY AND COMPANY (US) | 1990-02-20 | — | — | US | disclosed |
| US-4826992-A | MICROBIOCIDE INTERMEDIATES | ELI LILLY AND COMPANY (US) | 1989-05-02 | — | — | US | disclosed |
| EP-0203723-A1 | 2,3-(dihydro)bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-12-03 | — | — | EP | disclosed |
| EP-0203722-A1 | Bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-12-03 | — | — | EP | disclosed |
| EP-0202794-A1 | 7-Substituted-2,3-(Dihydro) bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-11-26 | — | — | EP | disclosed |
| EP-0202046-A1 | 7-Substituted bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061881-A1 | Compounds, compositions, and methods for stimulating neuronal growth and elongation | NGF, GAP43, BDNF | MEN1 3661/4885KMT2A 3886/4885NPC1 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.